I
Immuneering Corp
NASDAQ:IMRX
Immuneering Corp
NASDAQ:IMRX
Price:
1.47 USD
2.8%
Market Closed
Updated:
Apr 29, 2024
Immuneering Corp
Cash from Financing Activities
|
Immuneering Corp
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
Immuneering Corp
NASDAQ:IMRX
|
Cash from Financing Activities
$28.4m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Immuneering Corp's Cash from Financing Activities?
Cash from Financing Activities
28.4m
USD
28.4m
USD
Based on the financial report for Dec 31, 2023, Immuneering Corp's Cash from Financing Activities amounts to 28.4m USD.
What is Immuneering Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-9%
-9%
Over the last year, the Cash from Financing Activities growth was 142 105%. The average annual Cash from Financing Activities growth rates for Immuneering Corp have been -9% over the past three years .
You don't have any saved screeners yet
